Rani Net Borrowings from 2010 to 2025

RANI Stock  USD 1.39  0.01  0.71%   
Rani Therapeutics' Net Borrowings is increasing with slightly volatile movements from year to year. Net Borrowings is estimated to finish at about 35.7 M this year. Net Borrowings is the difference between the amount of new debt Rani Therapeutics Holdings has taken on and the amount of debt it has paid off during a given period. View All Fundamentals
 
Net Borrowings  
First Reported
2010-12-31
Previous Quarter
34 M
Current Value
35.7 M
Quarterly Volatility
13.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.2 M, Depreciation And Amortization of 925.5 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 6.22. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Rani Therapeutics Correlation against competitors.

Latest Rani Therapeutics' Net Borrowings Growth Pattern

Below is the plot of the Net Borrowings of Rani Therapeutics Holdings over the last few years. It is the difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period. Rani Therapeutics' Net Borrowings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Borrowings10 Years Trend
Slightly volatile
   Net Borrowings   
       Timeline  

Rani Net Borrowings Regression Statistics

Arithmetic Mean10,542,857
Coefficient Of Variation124.94
Mean Deviation10,837,160
Median4,035,000
Standard Deviation13,172,466
Sample Variance173.5T
Range40.3M
R-Value0.70
Mean Square Error95T
R-Squared0.49
Significance0
Slope1,934,367
Total Sum of Squares2602.7T

Rani Net Borrowings History

202535.7 M
202434 M
202229.6 M
2021-4.6 M

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' Net Borrowings, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Borrowings34 M35.7 M

Currently Active Assets on Macroaxis

When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(2.25)
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.